首页> 外文OA文献 >Quantitative nucleic acid sequence-based assay as a new molecular tool for detection and quantification of Leishmania parasites in skin biopsy samples
【2h】

Quantitative nucleic acid sequence-based assay as a new molecular tool for detection and quantification of Leishmania parasites in skin biopsy samples

机译:基于定量核酸序列的检测作为检测和定量皮肤活检样本中利什曼原虫的一种新型分子工具

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Currently available methods for the diagnosis of cutaneous leishmaniasis (CL) have low sensitivities or are unable to quantify the number of viable parasites. This constitutes a major obstacle for the diagnosis of the disease and for the study of the effectiveness of treatment schedules and urges the development of improved detection methods. In this study, quantitative nucleic acid sequence-based amplification (QT-NASBA) technology was used to detect and quantify Leishmania parasites in skin biopsy samples from CL patients. The assay is based on the detection of a small subunit rRNA (18S rRNA), which may allow for the detection of viable parasites. The QT-NASBA assay was evaluated using in vitro-cultured promastigotes and amastigotes and 2-mm skin biopsy samples from Old and New World CL patients. The study demonstrated that the lower detection limit of the QT-NASBA was two parasites per biopsy sample. Parasites could be quantified in a range of 2 to 11,300,000 parasites per biopsy sample. The QT-NASBA could detect levels of parasites 100-fold lower than those detected by conventional PCR. Test evaluation revealed that the QT-NASBA had a sensitivity of 97.5% and a specificity of 100% in the present study. The QT-NASBA is a highly sensitive and specific method that allows quantification of both Old and New World Leishmania parasites in skin biopsy samples and may provide an important tool for diagnosis as well as for monitoring the therapy of CL patients
机译:目前可用的诊断皮肤利什曼病(CL)的方法敏感性低或无法量化活寄生虫的数量。这对疾病的诊断和对治疗方案的有效性的研究构成了主要障碍,并敦促开发改进的检测方法。在这项研究中,基于定量核酸序列的扩增(QT-NASBA)技术用于检测和定量CL患者皮肤活检样品中的利什曼原虫寄生虫。该测定法基于对小亚基rRNA(18S rRNA)的检测,这可能允许检测活的寄生虫。使用体外培养的前鞭毛体和变形虫和2毫米旧世界和新世界CL患者的皮肤活检样品对QT-NASBA分析进行了评估。研究表明,QT-NASBA的检测下限是每个活检样本有两个寄生虫。每个活检样本中的寄生虫数量可定为2至1,130万。 QT-NASBA可以检测到的寄生虫水平比常规PCR检测的低100倍。测试评估显示,在本研究中,QT-NASBA的灵敏度为97.5%,特异性为100%。 QT-NASBA是一种高度灵敏和特异的方法,可以定量检测皮肤活检样品中的新旧利什曼原虫,并且可以为诊断和监测CL患者的治疗提供重要工具

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号